Cancer statistics, 2013.

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88

Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity. J Clin Oncol (2014) 6.62

Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med (2014) 6.54

Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92

Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science (2014) 5.63

Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med (2013) 4.09

Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med (2014) 4.01

Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nat Med (2014) 3.75

Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol (2015) 3.62

Restoration of Patency to Central Airways Occluded by Malignant Endobronchial Tumors Using Intratumoral Injection of Cisplatin. Ann Am Thorac Soc (2015) 3.55

American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16

Organoid models of human and mouse ductal pancreatic cancer. Cell (2014) 2.99

Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg (2015) 2.96

Breast cancer in female survivors of Wilms tumor: a report from the national Wilms tumor late effects study. Cancer (2014) 2.94

Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88

Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma. J Clin Oncol (2014) 2.85

Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77

Alveolar progenitor and stem cells in lung development, renewal and cancer. Nature (2014) 2.71

RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol (2015) 2.60

Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res (2014) 2.51

The role of the fallopian tube in the origin of ovarian cancer. Am J Obstet Gynecol (2013) 2.47

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc Natl Acad Sci U S A (2014) 2.46

Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol (2015) 2.46

Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol (2013) 2.27

Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. J Thorac Oncol (2014) 2.24

Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol (2014) 2.23

Utilization of renal mass biopsy in patients with renal cell carcinoma. Urology (2014) 2.23

Survival among patients with pancreatic cancer and long-standing or recent-onset diabetes mellitus. J Clin Oncol (2014) 2.21

Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19

Risk of incisional hernia after minimally invasive and open radical prostatectomy. J Urol (2013) 2.18

The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab (2013) 2.17

Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes. Nat Genet (2014) 2.11

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer (2014) 2.08

Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol (2015) 2.07

The effect of resistance exercise on all-cause mortality in cancer survivors. Mayo Clin Proc (2014) 2.06

Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol (2014) 2.05

Subcentimeter pulmonary nodules are not associated with disease progression in patients with renal cell carcinoma. J Urol (2014) 2.05

Neutrophil extracellular traps sequester circulating tumor cells and promote metastasis. J Clin Invest (2013) 2.03

Facilitating endoscopic submucosal dissection: the suture-pulley method significantly improves procedure time and minimizes technical difficulty compared with conventional technique: an ex vivo study (with video). Gastrointest Endosc (2014) 2.02

A pilot study to develop a diagnostic test for pancreatic ductal adenocarcinoma based on differential expression of select miRNA in plasma and bile. Am J Gastroenterol (2014) 2.02

Increased Expression of HER2, HER3, and HER2:HER3 Heterodimers in HPV-Positive HNSCC Using a Novel Proximity-Based Assay: Implications for Targeted Therapies. Clin Cancer Res (2015) 2.01

Correlation of (18)F-FDG avid volumes on pre-radiation therapy and post-radiation therapy FDG PET scans in recurrent lung cancer. Int J Radiat Oncol Biol Phys (2014) 2.01

Epigenome-wide DNA methylation landscape of melanoma progression to brain metastasis reveals aberrations on homeobox D cluster associated with prognosis. Hum Mol Genet (2013) 1.95

Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst (2014) 1.93

Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol (2013) 1.92

Central nervous system cancers. J Natl Compr Canc Netw (2013) 1.82

Bisphenol A promotes human prostate stem-progenitor cell self-renewal and increases in vivo carcinogenesis in human prostate epithelium. Endocrinology (2014) 1.81

Hyperglycemia, insulin resistance, impaired pancreatic β-cell function, and risk of pancreatic cancer. J Natl Cancer Inst (2013) 1.80

Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med (2013) 1.79

Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79

TALEN-engineered AR gene rearrangements reveal endocrine uncoupling of androgen receptor in prostate cancer. Proc Natl Acad Sci U S A (2013) 1.77

Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma. Nat Rev Clin Oncol (2013) 1.77

Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst (2014) 1.75

Impact of obesity on the survival of patients with early-stage squamous cell carcinoma of the oral tongue. Cancer (2014) 1.71

Retracted Expression of microRNA-497 and its prognostic significance in human breast cancer. Diagn Pathol (2013) 1.70

Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70

Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol (2014) 1.69

Augmentation of response to chemotherapy by microRNA-506 through regulation of RAD51 in serous ovarian cancers. J Natl Cancer Inst (2015) 1.68

Accuracy of fecal immunochemical tests for colorectal cancer: systematic review and meta-analysis. Ann Intern Med (2014) 1.68

Molecular genetics of clear-cell renal cell carcinoma. J Clin Oncol (2014) 1.65

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies. Int J Hematol (2013) 1.64

DNA methyltransferases: a novel target for prevention and therapy. Front Oncol (2014) 1.62

Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial. Cancer Epidemiol Biomarkers Prev (2014) 1.61

Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. BMJ (2015) 1.61

The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Ann Surg Oncol (2014) 1.58

Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58

Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol (2014) 1.57

Comparative effects of two different forms of selenium on oxidative stress biomarkers in healthy men: a randomized clinical trial. Cancer Prev Res (Phila) (2014) 1.57

Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. Nat Genet (2016) 1.57

Reproductive risk factors and breast cancer subtypes: a review of the literature. Breast Cancer Res Treat (2014) 1.56

Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med (2013) 1.56

Using Twitter for breast cancer prevention: an analysis of breast cancer awareness month. BMC Cancer (2013) 1.55

Patient-reported outcomes in randomised controlled trials of prostate cancer: methodological quality and impact on clinical decision making. Eur Urol (2013) 1.54

Cancer-specific survival after metastasis following primary radical prostatectomy compared with radiation therapy in prostate cancer patients: results of a population-based, propensity score-matched analysis. Eur Urol (2013) 1.54

Cardiovascular Disease Mortality Among Breast Cancer Survivors. Epidemiology (2016) 1.52

U.S. Food and Drug Administration approval summary: omacetaxine mepesuccinate as treatment for chronic myeloid leukemia. Oncologist (2013) 1.52

The preoperative lymphocyte to monocyte ratio predicts clinical outcome in patients with stage III colon cancer. Br J Cancer (2013) 1.52

MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model. Gut (2015) 1.51

Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointest Endosc (2015) 1.51

Primary care utilization and colorectal cancer incidence and mortality among Medicare beneficiaries: a population-based, case-control study. Ann Intern Med (2013) 1.51

Prognostic value of PLR in various cancers: a meta-analysis. PLoS One (2014) 1.50

The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'. Support Care Cancer (2014) 1.49

A comparison of the effects of epidural analgesia versus traditional pain management on outcomes after gastric cancer resection: a population-based study. Reg Anesth Pain Med (2014) 1.49

Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer (2016) 1.49

Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma. JAMA Oncol (2015) 1.49

Biomarkers in prostate cancer surveillance and screening: past, present, and future. Ther Adv Urol (2013) 1.48

Intraoperative molecular imaging can identify lung adenocarcinomas during pulmonary resection. J Thorac Cardiovasc Surg (2015) 1.48

A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol (2014) 1.48

Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer (2015) 1.48

Comparative effectiveness of screening strategies for Lynch syndrome. J Natl Cancer Inst (2015) 1.47

Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer. Clin Cancer Res (2015) 1.47

Synergistic effects of concurrent blockade of PI3K and MEK pathways in pancreatic cancer preclinical models. PLoS One (2013) 1.47

OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo. Mol Cancer (2015) 1.47

Circulating tumor cells exhibit a biologically aggressive cancer phenotype accompanied by selective resistance to chemotherapy. Cancer Lett (2014) 1.46

Joint association of genome-wide association study-identified susceptibility loci and dietary patterns in risk of renal cell carcinoma among non-Hispanic whites. Am J Epidemiol (2014) 1.46

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis. Clin Cancer Res (2014) 1.46

Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell (2014) 1.45

Renal cell carcinoma. BMJ (2014) 1.45

Long-term survival rates after resection for locally advanced kidney cancer: Memorial Sloan Kettering Cancer Center 1989 to 2012 experience. J Urol (2014) 1.44

Antitumor and antimetastatic activities of chloroform extract of medicinal mushroom Cordyceps taii in mouse models. BMC Complement Altern Med (2015) 1.44

Cancer statistics, 2012. CA Cancer J Clin (2012) 87.38

Cancer statistics, 2014. CA Cancer J Clin (2014) 72.81

Cancer statistics, 2015. CA Cancer J Clin (2015) 57.51

Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin (2011) 30.81

Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin (2012) 14.47

Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer (2010) 13.27

Colorectal cancer statistics, 2014. CA Cancer J Clin (2014) 12.86

Cancer disparities by race/ethnicity and socioeconomic status. CA Cancer J Clin (2004) 12.55

Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin (2014) 11.09

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst (2005) 8.36

International variation in prostate cancer incidence and mortality rates. Eur Urol (2012) 8.04

Breast cancer statistics, 2013. CA Cancer J Clin (2013) 7.35

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst (2003) 7.06

Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer (2007) 6.84

Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol (2012) 6.37

Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer (2013) 6.23

Experiences of discrimination: validity and reliability of a self-report measure for population health research on racism and health. Soc Sci Med (2005) 6.14

Breast cancer statistics, 2011. CA Cancer J Clin (2011) 6.12

Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on U.S. cancer burden. Cancer (2002) 6.08

Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J Clin (2007) 5.67

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer (2009) 5.55

Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin (2007) 5.31

Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09

Cancer mortality in the United States by education level and race. J Natl Cancer Inst (2007) 4.77

Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin (2006) 4.73

Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer (2006) 4.71

Worldwide variations in colorectal cancer. CA Cancer J Clin (2009) 4.71

International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev (2009) 4.49

Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer (2013) 4.24

Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin (2012) 4.13

The global burden of cancer: priorities for prevention. Carcinogenesis (2009) 3.73

Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin (2014) 3.59

Cancer statistics for Hispanics/Latinos, 2012. CA Cancer J Clin (2012) 3.58

Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer (2012) 3.55

Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomarkers Prev (2009) 3.08

Under-use of smoking-cessation treatments: results from the National Health Interview Survey, 2000. Am J Prev Med (2005) 3.02

Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst (2006) 2.66

Racial disparities in stage-specific colorectal cancer mortality rates from 1985 to 2008. J Clin Oncol (2011) 2.58

Cancer statistics for African Americans. CA Cancer J Clin (2002) 2.45

Cancer statistics for African Americans, 2013. CA Cancer J Clin (2013) 2.44

International trends in liver cancer incidence rates. Cancer Epidemiol Biomarkers Prev (2011) 2.40

Contribution of screening and survival differences to racial disparities in colorectal cancer rates. Cancer Epidemiol Biomarkers Prev (2012) 2.39

Trends in Kaposi's sarcoma and non-Hodgkin's lymphoma incidence in the United States from 1973 through 1998. J Natl Cancer Inst (2002) 2.38

Trends in breast cancer by race and ethnicity. CA Cancer J Clin (2004) 2.19

Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06

Breast cancer incidence rates in U.S. women are no longer declining. Cancer Epidemiol Biomarkers Prev (2011) 2.06

Relationship of serum fibrosis markers with liver fibrosis stage and collagen content in patients with advanced chronic hepatitis C. Hepatology (2008) 2.02

Tobacco control in the United States--recent progress and opportunities. CA Cancer J Clin (2009) 1.97

The influence of sex, race/ethnicity, and educational attainment on human immunodeficiency virus death rates among adults, 1993-2007. Arch Intern Med (2012) 1.92

Cancer statistics for Hispanics, 2003. CA Cancer J Clin (2003) 1.88

Recent trends in Black-White disparities in cancer mortality. Cancer Epidemiol Biomarkers Prev (2008) 1.86

Pancreatic cancer death rates by race among US men and women, 1970-2009. J Natl Cancer Inst (2013) 1.85

Incidence of noncutaneous melanomas in the U.S. Cancer (2005) 1.85

How much of the decrease in cancer death rates in the United States is attributable to reductions in tobacco smoking? Tob Control (2006) 1.80

Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut (2010) 1.78

Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology (2006) 1.73

DNA polymorphisms and response to treatment in patients with chronic hepatitis C: results from the HALT-C trial. J Hepatol (2008) 1.71

State disparities in colorectal cancer mortality patterns in the United States. Cancer Epidemiol Biomarkers Prev (2011) 1.54

Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology (2010) 1.52

Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (2009) 1.46

Trends in the incidence of colorectal cancer in relation to county-level poverty among blacks and whites. J Natl Med Assoc (2008) 1.42

A new method of predicting US and state-level cancer mortality counts for the current calendar year. CA Cancer J Clin (2004) 1.42

Management trends in stage I testicular seminoma: Impact of race, insurance status, and treatment facility. Cancer (2014) 1.41

Trends in colorectal cancer incidence rates in the United States by tumor location and stage, 1992-2008. Cancer Epidemiol Biomarkers Prev (2012) 1.36

Secular trends in mortality from common cancers in the United States by educational attainment, 1993-2001. J Natl Cancer Inst (2008) 1.34

A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin (2007) 1.33

Trends in colorectal cancer incidence rates by age, race/ethnicity, and indices of access to medical care, 1995–2004 (United States). Cancer Causes Control (2009) 1.33

Cancer incidence patterns among adolescents and young adults in the United States. Cancer Causes Control (2005) 1.25

Widening socioeconomic disparities in cervical cancer mortality among women in 26 states, 1993-2007. Cancer (2012) 1.21

Association of cutaneous melanoma incidence with area-based socioeconomic indicators-United States, 2004-2006. J Am Acad Dermatol (2011) 1.20

Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006. J Am Acad Dermatol (2011) 1.20

Subsite-specific colorectal cancer incidence rates and stage distributions among Asians and Pacific Islanders in the United States, 1995 to 1999. Cancer Epidemiol Biomarkers Prev (2004) 1.19

Body mass index in young adulthood and premature death: analyses of the US National Health Interview Survey linked mortality files. Am J Epidemiol (2011) 1.15

Disparities in breast cancer prognostic factors by race, insurance status, and education. Cancer Causes Control (2010) 1.15

Predicting US- and state-level cancer counts for the current calendar year: Part II: evaluation of spatiotemporal projection methods for incidence. Cancer (2012) 1.14

Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006. Cancer Epidemiol Biomarkers Prev (2010) 1.12

Outcome of older patients with acute myeloid leukemia: an analysis of SEER data over 3 decades. Cancer (2013) 1.11

Temporal trends in breast cancer mortality by state and race. Cancer Causes Control (2008) 1.11

Age-specific trends in black-white disparities in cervical cancer incidence in the United States: 1975-2009. Gynecol Oncol (2012) 1.05

Insurance status is related to diffuse large B-cell lymphoma survival. Cancer (2014) 1.04

Interpreting cancer trends. Ann N Y Acad Sci (2006) 1.03

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology (2009) 1.03

Social disparities in the burden of occupational exposures: results of a cross-sectional study. Am J Ind Med (2007) 1.02

U.S. congressional district cancer death rates. Int J Health Geogr (2006) 1.00

Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol (2008) 0.96

Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology (2011) 0.95

AACR Cancer Progress Report 2013. Clin Cancer Res (2013) 0.95

Work-to-family spillover and fruit and vegetable consumption among construction laborers. Am J Health Promot (2007) 0.95

The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? Future Oncol (2013) 0.95

Association of race/ethnicity, socioeconomic status, and breast cancer subtypes in the National Cancer Data Base (2010-2011). Breast Cancer Res Treat (2014) 0.95

Cancer-related risk factors and preventive measures in US Hispanics/Latinos. CA Cancer J Clin (2012) 0.95

Trends in colorectal cancer screening with home-based fecal occult blood tests in adults ages 50 to 64 years, 2000-2008. Cancer (2012) 0.94

Influence of rules from the Tenth Revision of the International Classification of Diseases on U.S. cancer mortality trends. J Natl Cancer Inst (2003) 0.94